Robert Behrens is an Oncology physician affiliated with Iowa Oncology Research Association. OpenAlex indexes 61 publications with 1,275 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1221 Pleasant St
Ste 100
Des Moines, IA 50309
Telephone
515-282-2921Provider last certified this registry record 3 Feb 2025.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ADC Therapeutics America, Inc.Program year20231 payment
- Adaptive Biotechnologies CorporationProgram year20221 payment
- Acrotech Biopharma LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
80.9%PD-1 inhibitor33.7%Pembrolizumab64%Nivolumab36%Part B, office-administered≥57 patientsCD38-directed Cytolytic Antibody9.8%Daratumumab100%Part B, office-administered≥21 patients+ 17 more classes in this area
Metabolism & gastrointestinal
11.3%Substance P/Neurokinin-1 Receptor Antagonist6.6%Aprepitant100%Part B, office-administered≥45 patientsSerotonin-3 Receptor Antagonist3.3%Ondansetron hydrochloride64%Palonosetron hcl36%Ondansetron Hcl1%Ondansetron Odt0%Part D + Part B≥171 patients+ 5 more classes in this area
Sensory organs
3%Corticosteroid3%Dexamethasone sodium phosphate99%Dexamethasone1%Part D + Part B≥160 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2008–2020 per NIH RePORTER. The latest:
- Iowa-Wide Oncology Research Coalition (I-WORC)
Iowa Oncology Research Association
FY2020$1,225,688UG1CA189816 - Iowa-Wide Oncology Research Coalition (I-WORC)
Iowa Oncology Research Association
FY2019$1,117,819UG1CA189816 - Iowa-Wide Oncology Research Coalition (I-WORC)
Iowa Oncology Research Association
FY2018$1,177,581UG1CA189816
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
New England Journal of Medicine
2026
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”